Roche Sees Signs Esbriet May Extend Lives in Deadly Lung AilmentBy
Esbriet cuts risk of death by 38% after 2 years of treatment
Drug may earn Roche more than CHF2b in sales by 2020
Roche Holding AG said there’s evidence its Esbriet treatment for a rare and deadly lung disease can extend lives.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.